Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 291

1.

Donor lymphocytes expressing the herpes simplex virus thymidine kinase suicide gene: detailed immunological function following add-back after haplo-identical transplantation.

Hashimoto H, Kitano S, Yamagata S, Miyagi Maeshima A, Ueda R, Ito A, Tada K, Fuji S, Yamashita T, Tomura D, Nukaya I, Mineno J, Fukuda T, Mori S, Takaue Y, Heike Y.

Cytotherapy. 2015 Dec;17(12):1820-30. doi: 10.1016/j.jcyt.2015.08.005. Epub 2015 Oct 6.

PMID:
26452983
2.

Erratum to: Infusion of donor lymphocytes expressing the herpes simplex virus thymidine kinase suicide gene for recurrent hematologic malignancies after allogeneic hematopoietic stem cell transplantation.

Hashimoto H, Kitano S, Ueda R, Ito A, Tada K, Fuji S, Kim SW, Yamashita T, Tomura D, Nukaya I, Mineno J, Fukuda T, Mori S, Takaue Y, Heike Y.

Int J Hematol. 2015 Oct;102(4):506. doi: 10.1007/s12185-015-1866-1. No abstract available.

PMID:
26362857
3.

Infusion of donor lymphocytes expressing the herpes simplex virus thymidine kinase suicide gene for recurrent hematologic malignancies after allogeneic hematopoietic stem cell transplantation.

Hashimoto H, Kitano S, Ueda R, Ito A, Tada K, Fuji S, Yamashita T, Tomura D, Nukaya I, Mineno J, Fukuda T, Mori S, Takaue Y, Heike Y.

Int J Hematol. 2015 Jul;102(1):101-10. doi: 10.1007/s12185-015-1801-5. Epub 2015 May 7. Erratum in: Int J Hematol. 2015 Oct;102(4):506.

PMID:
25948083
4.

In vivo T-cell depletion with alemtuzumab in allogeneic hematopoietic stem cell transplantation: Combined results of two studies on aplastic anemia and HLA-mismatched haploidentical transplantation.

Kanda Y, Oshima K, Kako S, Fukuda T, Uchida N, Miyamura K, Kondo Y, Nakao S, Nagafuji K, Miyamoto T, Kurokawa M, Okoshi Y, Chiba S, Ohashi Y, Takaue Y, Taniguchi S.

Am J Hematol. 2013 Apr;88(4):294-300. doi: 10.1002/ajh.23392. Epub 2013 Feb 28.

5.

Diagnosis and evaluation of intestinal graft-versus-host disease after allogeneic hematopoietic stem cell transplantation following reduced-intensity and myeloablative conditioning regimens.

Yamasaki S, Miyagi-Maeshima A, Kakugawa Y, Matsuno Y, Ohara-Waki F, Fuji S, Morita-Hoshi Y, Mori M, Kim SW, Mori S, Fukuda T, Tanosaki R, Shimoda T, Tobinai K, Saito D, Takaue Y, Teshima T, Heike Y.

Int J Hematol. 2013 Mar;97(3):421-6. doi: 10.1007/s12185-013-1297-9. Epub 2013 Feb 23.

PMID:
23435651
6.

Comparison of outcomes after allogeneic hematopoietic stem cell transplantation in patients with follicular lymphoma, diffuse large B-cell lymphoma associated with follicular lymphoma, or de novo diffuse large B-cell lymphoma.

Tada K, Kim SW, Asakura Y, Hiramoto N, Yakushijin K, Kurosawa S, Tajima K, Mori S, Heike Y, Tanosaki R, Maeshima AM, Taniguchi H, Furuta K, Kagami Y, Matsuno Y, Tobinai K, Takaue Y, Fukuda T.

Am J Hematol. 2012 Aug;87(8):770-5. doi: 10.1002/ajh.23246. Epub 2012 May 28.

7.

Real-time in vivo cellular imaging of graft-versus-host disease and its reaction to immunomodulatory reagents.

Yamazaki T, Aoki K, Heike Y, Kim SW, Ochiya T, Wakeda T, Hoffman RM, Takaue Y, Nakagama H, Ikarashi Y.

Immunol Lett. 2012 May 30;144(1-2):33-40. doi: 10.1016/j.imlet.2012.03.004. Epub 2012 Mar 15.

PMID:
22426442
8.

Phase 1 trial of Wilms tumor 1 (WT1) peptide vaccine and gemcitabine combination therapy in patients with advanced pancreatic or biliary tract cancer.

Kaida M, Morita-Hoshi Y, Soeda A, Wakeda T, Yamaki Y, Kojima Y, Ueno H, Kondo S, Morizane C, Ikeda M, Okusaka T, Takaue Y, Heike Y.

J Immunother. 2011 Jan;34(1):92-9. doi: 10.1097/CJI.0b013e3181fb65b9.

PMID:
21150717
9.

A Markov decision analysis of allogeneic hematopoietic cell transplantation versus chemotherapy in patients with acute myeloid leukemia in first remission.

Kurosawa S, Yamaguchi T, Miyawaki S, Uchida N, Kanamori H, Usuki K, Yamashita T, Watanabe M, Yakushiji K, Yano S, Nawa Y, Taguchi J, Takeuchi J, Tomiyama J, Nakamura Y, Miura I, Kanda Y, Takaue Y, Fukuda T.

Blood. 2011 Feb 17;117(7):2113-20. doi: 10.1182/blood-2010-05-285502. Epub 2010 Nov 24.

10.

Cost and effectiveness of reduced-intensity and conventional allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndrome.

Imataki O, Kamioka T, Fukuda T, Tanosaki R, Takaue Y.

Support Care Cancer. 2010 Dec;18(12):1565-9. doi: 10.1007/s00520-009-0779-z. Epub 2009 Nov 22.

PMID:
20967555
11.

Feasibility of reduced-intensity cord blood transplantation as salvage therapy for graft failure: results of a nationwide survey of adult patients.

Waki F, Masuoka K, Fukuda T, Kanda Y, Nakamae M, Yakushijin K, Togami K, Nishiwaki K, Ueda Y, Kawano F, Kasai M, Nagafuji K, Hagihara M, Hatanaka K, Taniwaki M, Maeda Y, Shirafuji N, Mori T, Utsunomiya A, Eto T, Nakagawa H, Murata M, Uchida T, Iida H, Yakushiji K, Yamashita T, Wake A, Takahashi S, Takaue Y, Taniguchi S.

Biol Blood Marrow Transplant. 2011 Jun;17(6):841-51. doi: 10.1016/j.bbmt.2010.09.005. Epub 2010 Sep 16.

12.

Hematopoietic stem cell transplantation for therapy-related myelodysplastic syndrome and acute leukemia: a single-center analysis of 47 patients.

Yokoyama H, Mori S, Kobayashi Y, Kurosawa S, Saito B, Fuji S, Maruyama D, Azuma T, Kim SW, Watanabe T, Tanosaki R, Tobinai K, Takaue Y, Fukuda T.

Int J Hematol. 2010 Sep;92(2):334-41. doi: 10.1007/s12185-010-0640-7. Epub 2010 Aug 4.

PMID:
20680530
13.

Comparison of allogeneic hematopoietic cell transplantation and chemotherapy in elderly patients with non-M3 acute myelogenous leukemia in first complete remission.

Kurosawa S, Yamaguchi T, Uchida N, Miyawaki S, Usuki K, Watanabe M, Yamashita T, Kanamori H, Tomiyama J, Nawa Y, Yano S, Takeuchi J, Yakushiji K, Sano F, Uoshima N, Yano T, Nannya Y, Moriuchi Y, Miura I, Takaue Y, Fukuda T.

Biol Blood Marrow Transplant. 2011 Mar;17(3):401-11. doi: 10.1016/j.bbmt.2010.07.013. Epub 2010 Jul 25.

14.

Prognostic factors and outcomes of adult patients with acute myeloid leukemia after first relapse.

Kurosawa S, Yamaguchi T, Miyawaki S, Uchida N, Sakura T, Kanamori H, Usuki K, Yamashita T, Okoshi Y, Shibayama H, Nakamae H, Mawatari M, Hatanaka K, Sunami K, Shimoyama M, Fujishima N, Maeda Y, Miura I, Takaue Y, Fukuda T.

Haematologica. 2010 Nov;95(11):1857-64. doi: 10.3324/haematol.2010.027516. Epub 2010 Jul 15.

15.

A potential activity of valproic acid in the stimulation of interleukin-3-mediated megakaryopoiesis and erythropoiesis.

Liu B, Ohishi K, Yamamura K, Suzuki K, Monma F, Ino K, Nishii K, Masuya M, Sekine T, Heike Y, Takaue Y, Katayama N.

Exp Hematol. 2010 Aug;38(8):685-95. doi: 10.1016/j.exphem.2010.03.019. Epub 2010 Apr 8. Erratum in: Exp Hematol. 2010 Sep;38(9):845. Nishii, Kazuhiro [added].

PMID:
20381581
16.

Identification of molecular markers for pre-engraftment immune reactions after cord blood transplantation by SELDI-TOF MS.

Morita-Hoshi Y, Mori SI, Soeda A, Wakeda T, Ohsaki Y, Shiwa M, Masuoka K, Wake A, Taniguchi S, Takaue Y, Heike Y.

Bone Marrow Transplant. 2010 Nov;45(11):1594-601. doi: 10.1038/bmt.2010.18. Epub 2010 Mar 15.

PMID:
20228853
17.

Outcome of 93 patients with relapse or progression following allogeneic hematopoietic cell transplantation.

Kurosawa S, Fukuda T, Tajima K, Saito B, Fuji S, Yokoyama H, Kim SW, Mori S, Tanosaki R, Heike Y, Takaue Y.

Am J Hematol. 2009 Dec;84(12):815-20. doi: 10.1002/ajh.21555.

18.

Regular dose of gemcitabine induces an increase in CD14+ monocytes and CD11c+ dendritic cells in patients with advanced pancreatic cancer.

Soeda A, Morita-Hoshi Y, Makiyama H, Morizane C, Ueno H, Ikeda M, Okusaka T, Yamagata S, Takahashi N, Hyodo I, Takaue Y, Heike Y.

Jpn J Clin Oncol. 2009 Dec;39(12):797-806. doi: 10.1093/jjco/hyp112. Epub 2009 Oct 1.

PMID:
19797418
19.

Decreased insulin secretion in patients receiving tacrolimus as GVHD prophylaxis after allogeneic hematopoietic SCT.

Fuji S, Kim SW, Mori S, Furuta K, Tanosaki R, Heike Y, Takaue Y, Fukuda T.

Bone Marrow Transplant. 2010 Feb;45(2):405-6. doi: 10.1038/bmt.2009.154. Epub 2009 Aug 3. No abstract available.

PMID:
19648969
20.

Intensive glucose control after allogeneic hematopoietic stem cell transplantation: a retrospective matched-cohort study.

Fuji S, Kim SW, Mori S, Kamiya S, Yoshimura K, Yokoyama H, Kurosawa S, Saito B, Takahashi T, Kuwahara S, Heike Y, Tanosaki R, Takaue Y, Fukuda T.

Bone Marrow Transplant. 2009 Jul;44(2):105-11. doi: 10.1038/bmt.2008.431. Epub 2009 Jan 19.

PMID:
19151794
21.

Positive impact of maintaining minimal caloric intake above 1.0 x basal energy expenditure on the nutritional status of patients undergoing allogeneic hematopoietic stem cell transplantation.

Fuji S, Kim SW, Fukuda T, Kamiya S, Kuwahara S, Takaue Y.

Am J Hematol. 2009 Jan;84(1):63-4. doi: 10.1002/ajh.21307. No abstract available.

22.

Busulfex (i.v. BU) and CY regimen before SCT: Japanese-targeted phase II pharmacokinetics combined study.

Kim SW, Mori SI, Tanosaki R, Fukuda T, Kami M, Sakamaki H, Yamashita T, Kodera Y, Terakura S, Taniguchi S, Miyakoshi S, Usui N, Yano S, Kawano Y, Nagatoshi Y, Harada M, Morishima Y, Okamoto S, Saito AM, Ohashi Y, Ueda R, Takaue Y.

Bone Marrow Transplant. 2009 Apr;43(8):611-7. doi: 10.1038/bmt.2008.372. Epub 2008 Nov 17.

PMID:
19011665
23.

Impact of T cell chimerism on clinical outcome in 117 patients who underwent allogeneic stem cell transplantation with a busulfan-containing reduced-intensity conditioning regimen.

Saito B, Fukuda T, Yokoyama H, Kurosawa S, Takahashi T, Fuji S, Takahashi N, Tajima K, Kim SW, Mori SI, Tanosaki R, Takaue Y, Heike Y.

Biol Blood Marrow Transplant. 2008 Oct;14(10):1148-1155. doi: 10.1016/j.bbmt.2008.07.013.

24.

Reduced-intensity unrelated donor bone marrow transplantation for hematologic malignancies.

Kim SW, Matsuo K, Fukuda T, Hara M, Matsue K, Taniguchi S, Eto T, Tanimoto M, Wake A, Hatanaka K, Nakao S, Ishida Y, Harada M, Utsunomiya A, Imamura M, Kanda Y, Sunami K, Kawano F, Takaue Y, Teshima T.

Int J Hematol. 2008 Oct;88(3):324-330. doi: 10.1007/s12185-008-0163-7. Epub 2008 Sep 17.

PMID:
18797985
25.

Insufficient ex vivo expansion of Valpha24(+) natural killer T cells in malignant lymphoma patients related to the suppressed expression of CD1d molecules on CD14(+) cells.

Imataki O, Heike Y, Makiyama H, Iizuka A, Ikarashi Y, Ishida T, Wakasugi H, Takaue Y.

Cytotherapy. 2008;10(5):497-506. doi: 10.1080/14653240802072747.

PMID:
18608348
26.

Small intestinal CMV disease detected by capsule endoscopy after allogeneic hematopoietic SCT.

Kakugawa Y, Kim SW, Takizawa K, Kikuchi T, Fujieda A, Waki F, Fukuda T, Saito Y, Shimoda T, Takaue Y, Saito D.

Bone Marrow Transplant. 2008 Aug;42(4):283-4. doi: 10.1038/bmt.2008.154. Epub 2008 May 26. No abstract available.

PMID:
18500371
27.

Characterization of acute graft-versus-host disease following reduced-intensity stem-cell transplantation from an HLA-identical related donor.

Murashige N, Kami M, Mori S, Katayama Y, Kobayashi K, Onishi Y, Hori A, Kishi Y, Hamaki T, Tajima K, Kanda Y, Tanosaki R, Takaue Y.

Am J Hematol. 2008 Aug;83(8):630-4. doi: 10.1002/ajh.21197.

28.

Preengraftment serum C-reactive protein (CRP) value may predict acute graft-versus-host disease and nonrelapse mortality after allogeneic hematopoietic stem cell transplantation.

Fuji S, Kim SW, Fukuda T, Mori S, Yamasaki S, Morita-Hoshi Y, Ohara-Waki F, Heike Y, Tobinai K, Tanosaki R, Takaue Y.

Biol Blood Marrow Transplant. 2008 May;14(5):510-7. doi: 10.1016/j.bbmt.2008.02.008.

29.

Allo-SCT using reduced-intensity conditioning against advanced pancreatic cancer: a Japanese survey.

Kanda Y, Omuro Y, Baba E, Oshima K, Nagafuji K, Heike Y, Takaue Y, Sasaki T, Sakamaki H, Harada M.

Bone Marrow Transplant. 2008 Jul;42(2):99-103. doi: 10.1038/bmt.2008.94. Epub 2008 Apr 7.

PMID:
18391987
30.

Segregated graft-versus-tumor effect between CNS and non-CNS lesions of Ewing's sarcoma family of tumors.

Hosono A, Makimoto A, Kawai A, Takaue Y.

Bone Marrow Transplant. 2008 Jun;41(12):1067-8. doi: 10.1038/bmt.2008.26. Epub 2008 Mar 10. No abstract available.

PMID:
18332914
31.

Infectious complications in chronic graft-versus-host disease: a retrospective study of 145 recipients of allogeneic hematopoietic stem cell transplantation with reduced- and conventional-intensity conditioning regimens.

Yamasaki S, Heike Y, Mori S, Fukuda T, Maruyama D, Kato R, Usui E, Koido K, Kim S, Tanosaki R, Tobinai K, Teshima T, Takaue Y.

Transpl Infect Dis. 2008 Jul;10(4):252-9. doi: 10.1111/j.1399-3062.2007.00291.x. Epub 2008 Jan 9.

PMID:
18194371
32.

Functional analysis of cytomegalovirus-specific T lymphocytes compared to tetramer assay in patients undergoing hematopoietic stem cell transplantation.

Morita-Hoshi Y, Heike Y, Kawakami M, Sugita T, Miura O, Kim SW, Mori SI, Fukuda T, Tanosaki R, Tobinai K, Takaue Y.

Bone Marrow Transplant. 2008 Mar;41(6):515-21. Epub 2007 Nov 19.

PMID:
18026143
33.

Interleukin (IL)-4 promotes T helper type 2-biased natural killer T (NKT) cell expansion, which is regulated by NKT cell-derived interferon-gamma and IL-4.

Iizuka A, Ikarashi Y, Yoshida M, Heike Y, Takeda K, Quinn G, Wakasugi H, Kitagawa M, Takaue Y.

Immunology. 2008 Jan;123(1):100-7. Epub 2007 Nov 14.

34.

Hyperglycemia during the neutropenic period is associated with a poor outcome in patients undergoing myeloablative allogeneic hematopoietic stem cell transplantation.

Fuji S, Kim SW, Mori S, Fukuda T, Kamiya S, Yamasaki S, Morita-Hoshi Y, Ohara-Waki F, Honda O, Kuwahara S, Tanosaki R, Heike Y, Tobinai K, Takaue Y.

Transplantation. 2007 Oct 15;84(7):814-20.

PMID:
17984832
35.

T-cell large granular lymphocyte leukemia of donor origin after cord blood transplantation.

Kusumoto S, Mori S, Nosaka K, Morita-Hoshi Y, Onishi Y, Kim SW, Watanabe T, Heike Y, Tanosaki R, Takaue Y, Tobinai K.

Clin Lymphoma Myeloma. 2007 Jul;7(7):475-9.

PMID:
17875238
36.

Comparable antileukemia/lymphoma effects in nonremission patients undergoing allogeneic hematopoietic cell transplantation with a conventional cytoreductive or reduced-intensity regimen.

Maruyama D, Fukuda T, Kato R, Yamasaki S, Usui E, Morita-Hoshi Y, Kim SW, Mori S, Heike Y, Makimoto A, Tajima K, Tanosaki R, Tobinai K, Takaue Y.

Biol Blood Marrow Transplant. 2007 Aug;13(8):932-41. Epub 2007 May 29.

37.

Prospective phase II trial to evaluate the complications and kinetics of chimerism induction following allogeneic hematopoietic stem cell transplantation with fludarabine and busulfan.

Saito AM, Kami M, Mori S, Kanda Y, Suzuki R, Mineishi S, Takami A, Taniguchi S, Takemoto Y, Hara M, Yamaguchi M, Hino M, Yoshida T, Kim SW, Hori A, Ohashi Y, Takaue Y.

Am J Hematol. 2007 Oct;82(10):873-80.

38.

Unrelated-donor bone marrow transplantation with a conditioning regimen including fludarabine, busulfan, and 4 Gy total body irradiation.

Onishi Y, Mori S, Kusumoto S, Sugimoto K, Akahane D, Morita-Hoshi Y, Kim SW, Fukuda T, Heike Y, Tanosaki R, Tobinai K, Takaue Y.

Int J Hematol. 2007 Apr;85(3):256-63.

PMID:
17483064
39.

Early detection of plasma cytomegalovirus DNA by real-time PCR after allogeneic hematopoietic stem cell transplantation.

Onishi Y, Mori S, Higuchi A, Kim SW, Fukuda T, Heike Y, Tanosaki R, Minematsu T, Takaue Y, Sasaki T, Furuta K.

Tohoku J Exp Med. 2006 Oct;210(2):125-35.

40.

Pleiotropic role of histone deacetylases in the regulation of human adult erythropoiesis.

Yamamura K, Ohishi K, Katayama N, Yu Z, Kato K, Masuya M, Fujieda A, Sugimoto Y, Miyata E, Shibasaki T, Heike Y, Takaue Y, Shiku H.

Br J Haematol. 2006 Oct;135(2):242-53. Epub 2006 Aug 25. Erratum in: Br J Haematol. 2007 Jan;136(1):175-6.

PMID:
16939493
41.

Nutritional support for patients suffering from intestinal graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.

Imataki O, Nakatani S, Hasegawa T, Kondo M, Ichihashi K, Araki M, Ishida T, Kim SW, Mori S, Fukuda T, Tobinai K, Tanosaki R, Makimoto A, Takaue Y.

Am J Hematol. 2006 Oct;81(10):747-52.

42.

Modulation of acute graft-versus-host disease and chimerism after adoptive transfer of in vitro-expanded invariant Valpha14 natural killer T cells.

Kuwatani M, Ikarashi Y, Iizuka A, Kawakami C, Quinn G, Heike Y, Yoshida M, Asaka M, Takaue Y, Wakasugi H.

Immunol Lett. 2006 Jul 15;106(1):82-90. Epub 2006 May 23.

PMID:
16806496
43.

Coincidental outbreak of methicillin-resistant Staphylococcus aureus in a hematopoietic stem cell transplantation unit.

Imataki O, Makimoto A, Kato S, Bannai T, Numa N, Nukui Y, Morisawa Y, Ishida T, Kami M, Fukuda T, Mori S, Tanosaki R, Takaue Y.

Am J Hematol. 2006 Sep;81(9):664-9.

44.

Efficient ex vivo expansion of Valpha24+ NKT cells derived from G-CSF-mobilized blood cells.

Imataki O, Heike Y, Ishida T, Takaue Y, Ikarashi Y, Yoshida M, Wakasugi H, Kakizoe T.

J Immunother. 2006 May-Jun;29(3):320-7.

PMID:
16699375
45.

Endoscopic evaluation for cytomegalovirus enterocolitis after allogeneic haematopoietic stem cell transplantation.

Kakugawa Y, Kami M, Kozu T, Kobayashi N, Shoda H, Matsuda T, Saito Y, Oda I, Gotoda T, Mori S, Tanosaki R, Murashige N, Hamaki T, Mineishi S, Takaue Y, Shimoda T, Saito D.

Gut. 2006 Jun;55(6):895-6. No abstract available.

46.
47.

Monitoring of WT1-specific cytotoxic T lymphocytes after allogeneic hematopoietic stem cell transplantation.

Morita Y, Heike Y, Kawakami M, Miura O, Nakatsuka S, Ebisawa M, Mori S, Tanosaki R, Fukuda T, Kim SW, Tobinai K, Takaue Y.

Int J Cancer. 2006 Sep 15;119(6):1360-7.

48.

Prospective trial of high-dose chemotherapy followed by infusions of peripheral blood stem cells and dose-escalated donor lymphocytes for relapsed leukemia after allogeneic stem cell transplantation.

Takami A, Okumura H, Yamazaki H, Kami M, Kim SW, Asakura H, Endo T, Nishio M, Minauchi K, Kumano K, Sugimori N, Mori S, Takemoto Y, Shimadoi S, Ozaki J, Takaue Y, Nakao S.

Int J Hematol. 2005 Dec;82(5):449-55.

PMID:
16533751
49.

Myeloablative allogeneic hematopoietic stem cell transplantation for non-Hodgkin lymphoma: a nationwide survey in Japan.

Kim SW, Tanimoto TE, Hirabayashi N, Goto S, Kami M, Yoshioka S, Uchida T, Kishi K, Tanaka Y, Kohno A, Kasai M, Higuchi M, Kasai M, Mori S, Fukuda T, Izutsu K, Sao H, Ishikawa T, Ichinohe T, Takeuchi K, Tajima K, Tanosaki R, Harada M, Taniguchi S, Tobinai K, Hotta T, Takaue Y.

Blood. 2006 Jul 1;108(1):382-9. Epub 2006 Mar 7.

50.

Peripheral blood stem cell mobilization by granulocyte colony-stimulating factor alone and engraftment kinetics following autologous transplantation in children and adolescents with solid tumor.

Watanabe H, Watanabe T, Suzuya H, Wakata Y, Kaneko M, Onishi T, Okamoto Y, Abe T, Kawano Y, Kagami S, Takaue Y.

Bone Marrow Transplant. 2006 Apr;37(7):661-8.

PMID:
16489358

Supplemental Content

Loading ...
Support Center